姑息化疗EGFR-TKI治疗失败后晚期非小细胞肺癌临床疗效观察

Clinical observation of palliative chemotherapy for 16 patients with advanced non-small cell lung cancer failed in treatment of EGFR-TKI

目的观察晚期非小细胞肺癌EGFR-TKI治疗失败后姑息化疗的疗效及不良反应。方法姑息化疗EGFR-TKI治疗失败的晚期非小细胞肺癌患者16例,其中10例采取联合化疗,6例采取单药化疗。结果 16例患者中PR 1例,SD 10例,疾病控制率为68.8%;联合化疗组中位生存期13月,1年生存率60.0%;单药化疗组中位生存期8月,1年生存率33.3%,两组比较差异无统计学意义(P>0.05)。两组不良反应轻微,均可耐受。结论对于EGFR-TKI治疗失败而且体力状况较好的晚期NSCLC患者,可尝试采取姑息化疗。

Objective To observe the efficacy and toxicity of palliative chemotherapy for patients with advanced non-small cell lung cancer（NSCLC） failed in the treatment of EGFR-TKI.Methods Sixteen patients with advanced NSCLC failed in the treatment of EGFR-TKI were divided into two groups.Ten cases received combination chemotherapy and 6 cases were treated with single-agent chemotherapy.Results Among the 16 patients with advanced NSCLC failed in the treatment of EGFR-TKI,partial response（PR） accounted for 6.25%;stable disease（SD） accounted for 62.5%;disease control rate accounted for 68.8%.In combination chemotherapy group,the median survival time was 13 months;1-year survival rate was 60.0%.In single-agent chemotherapy groups,the median survival time was 8 months;1-year survival rate was 33.3%.There was no significant difference between the two groups（P〉0.05）.In two groups,the toxicities were mild and tolerable.Conclusion Treatment with palliative chemotherapy for patients with advanced NSCLC who fails in the treatment of EGFR-TKI and has a good physical strength condition might be feasible.